Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.
Positive preclinical results in a model of uveitis Development of the first class of biomedicines in ophthalmology with bio-HDL Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852